MedDataX Logo

Study of Undertreatment of Patients With Dyslipidemia in Bulgaria

NCT ID: NCT01075594

Last Updated: 2010-09-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-02-28

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to establish the proportion of Bulgarian patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Fourth Joint European Task Force guidelines.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyslipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Patients with dyslipidemia on lipid lowering therapy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks
* Signed Informed Consent

Exclusion Criteria

* Informed Consent not provided
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Blagoevgrad, , Bulgaria

Site Status

Research Site

Burgas, , Bulgaria

Site Status

Research Site

Haskovo, , Bulgaria

Site Status

Research Site

Montana, , Bulgaria

Site Status

Research Site

Pazardzhik, , Bulgaria

Site Status

Research Site

Pleven, , Bulgaria

Site Status

Research Site

Plovdiv, , Bulgaria

Site Status

Research Site

Rousse, , Bulgaria

Site Status

Research Site

Shumen, , Bulgaria

Site Status

Research Site

Sliven, , Bulgaria

Site Status

Research Site

Smolyan, , Bulgaria

Site Status

Research Site

Sofia, , Bulgaria

Site Status

Research Site

Stara Zagora, , Bulgaria

Site Status

Research Site

Varna, , Bulgaria

Site Status

Research Site

Veliko Tarnovo, , Bulgaria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Bulgaria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-CBG-CRE-2009/1

Identifier Type: -

Identifier Source: org_study_id